A new research study by Zynerba Pharmaceuticals is enrolling children and adolescents aged 3 to 17 years of age and who have Fragile X syndrome and are also experiencing behavioural-related issues.
This clinical trial is valuating investigational cannabidiol (CBD) gel in children and adolescents to assess whether it helps behavioural issues related to Fragile X syndrome, such as social anxiety, irritability and social unresponsiveness.

The study is enrolling participants in sites across several countries including Australia and the United States.  In Australia the enrolment sites are in Melbourne, Brisbane and Sydney, as was the case for the earlier Zynerba studies.

More information:  https://fragilexhelp.com.au/about/